Clinical trial
ALINC #17 Treatment for Patients With Low Risk Acute Lymphoblastic Leukemia: A Pediatric Oncology Group Phase III Study
NCT00005585 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- ALINC #17 Treatment for Patients With Low Risk Acute Lymphoblastic Leukemia: A Pediatric Oncology Group Phase III Study
- Lead sponsor
- Children's Oncology Group
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- April 30, 2000
- Completion date
- Not reported
- Enrollment
- 838 (actual)
- Sites
- 123
Conditions
As the registry lists them; a condition with its own page is linked.